Neurodegenerative diseases reveal pathways involving prolyl oligopeptidase, indicating its potential as a treatment target.
Neurodegenerative diseases, such as Alzheimer's and Parkinson's, pose a growing global health burden. Prolyl oligopeptidase (PREP) has emerged as a potential therapeutic target in these diseases. Recent studies have shown...
No takes yet. Share an insight, caveat, or question.
Jakub Rydzewski (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: